NCT04470063Unknown1 期
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases-Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 30
- 试验地点
- 12
- 主要终点
- The incidence and severity of adverse events to assess safety and tolerability.
研究概览
简要总结
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multi-dose DDO-3055 tablets in patients with anemia of non-dialysis chronic kidney diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CKD anemia aged 18-70 years who were not on dialysis and were not expected to undergo dialysis during the study period, regardless of gender;
- •Male weight≥50kg, female weight≥45kg, and 19kg/m2≤BMI<28kg/m2;
- •Signed informed consent.
排除标准
- •Allergic constitution, suspected to be allergic to the study drug or any component in the study drug;
- •Patients with acute coronary syndrome, stroke, thromboembolism (such as deep vein thrombosis or pulmonary embolism) or a history of seizures within 6 months before screening;
- •Patients with uncontroll ed hypertension;
- •New York Heart Association grade III or IV congestive heart failure at the time of screening;
- •ALT,AST or total bilirubin exceeds 1.5 times the upper limit of normal value (ULN) during the screening period;
- •Suffer from anemia other than CKD.
- •Patients with a history of chronic liver disease;
- •Patients with active bleeding or known coagulopathy;
- •Patients who have any previous organ transplant or plan to perform organ transplant;
- •Intravenous iron supplementation within 1 month before screening;
- •Used erythropoiesis stimulator (ESAs), hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), androgen, blood transfusion therapy within 3 months before screening;
- •Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, and human immunodeficiency virus (HIV) antibody were positive;
- •Patients with blood loss ≥400mL within 3 months before screening;
- •Subjects who have taken other clinical trial drugs or are expected to have a legacy effect of the trial treatment;
- •Participants who are unwilling to take contraception or male subjects who cannot guarantee not to donate sperm during the trial and within 30 days after the last dose; female subjects with fertility who did not use contraception for at least 14 days before dosing;or male and female subjects who did not agree to use physical contraception during the trial;
- •Patients who had a positive blood pregnancy test and were breastfeeding at the time of screening;
- •According to the study physician's judgment, there may be any other anemia factors that may exist, any possibility to increase the risk of the study, affect the subject's compliance with the protocol, or affect the physical or psychological disease or condition of the subject to complete the study.
研究组 & 干预措施
group A
Experimental
干预措施: DDO-3055 tablets (Drug)
group A
Experimental
干预措施: Placebo (Drug)
group B
Experimental
干预措施: DDO-3055 tablets (Drug)
group B
Experimental
干预措施: Placebo (Drug)
group C
Experimental
干预措施: DDO-3055 tablets (Drug)
group C
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
The incidence and severity of adverse events to assess safety and tolerability.
时间窗: up to 37 days
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
Unknown
1 期
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.Renal AnemiaNCT04775615Jiangsu HengRui Medicine Co., Ltd.36
已完成
1 期
A Multiple Ascending Dose Trial of HRS-2129 in Healthy SubjectsPainNCT06742840Shandong Suncadia Medicine Co., Ltd.23
已完成
1 期
A Single Dose Escalation Trial of HRS-2129 in Healthy SubjectsPainNCT06619392Shandong Suncadia Medicine Co., Ltd.44
已完成
1 期
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese SubjectsOverweight or ObesityNCT06621316Shandong Suncadia Medicine Co., Ltd.74
已完成
1 期
A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy SubjectsDyslipidemiaNCT06732154Fujian Shengdi Pharmaceutical Co., Ltd.50